Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Goetz

Showing results (331-340 of 397) with videos related to

Pageof 40
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 20, 2015
A First-in-Human Phase I Study of the Oral p38 MAPK Inhibitor, Ralimetinib (LY2228820 Dimesylate), in Patients with Advanced CancerAmita Patnaik, Paul Haluska, Anthony W Tolcher, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 15, 2004
Percutaneous image-guided radiofrequency ablation of painful metastases involving bone: a multicenter studyMatthew P Goetz, Matthew R Callstrom, J William Charboneau, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 15, 2025
Corrigendum to "Abemaciclib plus a nonsteroidal aromatase inhibitor as initial therapy for HR+, HER2- advanced breast cancer: final overall survival results of MONARCH 3": [Ann Oncol 2024; 35: 718-727]M P Goetz, M Toi, J Huober, et al.
Breast Cancer Research : BCR|May 21, 2020
Antitumor activity of Z-endoxifen in aromatase inhibitor-sensitive and aromatase inhibitor-resistant estrogen receptor-positive breast cancerSwaathi Jayaraman, Xiaonan Hou, Mary J Kuffel, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 19, 2025
Overall survival with abemaciclib in early breast cancerS Johnston, M Martin, J O'Shaughnessy, et al.
Molecular Cancer Therapeutics|May 23, 2024
PKMYT1 Is a Marker of Treatment Response and a Therapeutic Target for CDK4/6 Inhibitor-Resistance in ER+ Breast CancerAnran Chen, Beom-Jun Kim, Aparna Mitra, et al.
Oncotarget|March 4, 2021
Phase 1 study of Z-endoxifen in patients with advanced gynecologic, desmoid, and hormone receptor-positive solid tumorsNaoko Takebe, Geraldine O'Sullivan Coyne, Shivaani Kummar, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 24, 2019
A combinatorial biomarker predicts pathologic complete response to neoadjuvant lapatinib and trastuzumab without chemotherapy in patients with HER2+ breast cancerJ Veeraraghavan, C De Angelis, R Mao, et al.
Breast Cancer Research : BCR|June 10, 2024
Pre-treatment peripheral blood immunophenotyping and response to neoadjuvant chemotherapy in operable breast cancerRoberto A Leon-Ferre, Kaitlyn R Whitaker, Vera J Suman, et al.
Journal of the National Cancer Institute|December 11, 2014
Loss of heterozygosity at the CYP2D6 locus in breast cancer: implications for germline pharmacogenetic studiesMatthew P Goetz, James X Sun, Vera J Suman, et al.
Pageof 40

Showing results (331-340 of 397) with videos related to

Sort By:
Pageof 40
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 20, 2015
A First-in-Human Phase I Study of the Oral p38 MAPK Inhibitor, Ralimetinib (LY2228820 Dimesylate), in Patients with Advanced CancerAmita Patnaik, Paul Haluska, Anthony W Tolcher, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 15, 2004
Percutaneous image-guided radiofrequency ablation of painful metastases involving bone: a multicenter studyMatthew P Goetz, Matthew R Callstrom, J William Charboneau, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 15, 2025
Corrigendum to "Abemaciclib plus a nonsteroidal aromatase inhibitor as initial therapy for HR+, HER2- advanced breast cancer: final overall survival results of MONARCH 3": [Ann Oncol 2024; 35: 718-727]M P Goetz, M Toi, J Huober, et al.
Breast Cancer Research : BCR|May 21, 2020
Antitumor activity of Z-endoxifen in aromatase inhibitor-sensitive and aromatase inhibitor-resistant estrogen receptor-positive breast cancerSwaathi Jayaraman, Xiaonan Hou, Mary J Kuffel, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 19, 2025
Overall survival with abemaciclib in early breast cancerS Johnston, M Martin, J O'Shaughnessy, et al.
Molecular Cancer Therapeutics|May 23, 2024
PKMYT1 Is a Marker of Treatment Response and a Therapeutic Target for CDK4/6 Inhibitor-Resistance in ER+ Breast CancerAnran Chen, Beom-Jun Kim, Aparna Mitra, et al.
Oncotarget|March 4, 2021
Phase 1 study of Z-endoxifen in patients with advanced gynecologic, desmoid, and hormone receptor-positive solid tumorsNaoko Takebe, Geraldine O'Sullivan Coyne, Shivaani Kummar, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 24, 2019
A combinatorial biomarker predicts pathologic complete response to neoadjuvant lapatinib and trastuzumab without chemotherapy in patients with HER2+ breast cancerJ Veeraraghavan, C De Angelis, R Mao, et al.
Breast Cancer Research : BCR|June 10, 2024
Pre-treatment peripheral blood immunophenotyping and response to neoadjuvant chemotherapy in operable breast cancerRoberto A Leon-Ferre, Kaitlyn R Whitaker, Vera J Suman, et al.
Journal of the National Cancer Institute|December 11, 2014
Loss of heterozygosity at the CYP2D6 locus in breast cancer: implications for germline pharmacogenetic studiesMatthew P Goetz, James X Sun, Vera J Suman, et al.
Pageof 40